- Home
- PSF vs CERS Comparison
PSF vs CERS Comparison
Compare PSF & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- CERS
- Stock Information
- Founded
- PSF 2010
- CERS 1991
- Country
- PSF United States
- CERS United States
- Employees
- PSF N/A
- CERS N/A
- Industry
- PSF Investment Managers
- CERS EDP Services
- Sector
- PSF Finance
- CERS Technology
- Exchange
- PSF Nasdaq
- CERS Nasdaq
- Market Cap
- PSF 236.8M
- CERS 265.7M
- IPO Year
- PSF N/A
- CERS 1997
- Fundamental
- Price
- PSF $20.53
- CERS $1.27
- Analyst Decision
- PSF
- CERS Strong Buy
- Analyst Count
- PSF 0
- CERS 2
- Target Price
- PSF N/A
- CERS $3.50
- AVG Volume (30 Days)
- PSF 25.0K
- CERS 882.9K
- Earning Date
- PSF 01-01-0001
- CERS 08-05-2025
- Dividend Yield
- PSF 7.69%
- CERS N/A
- EPS Growth
- PSF N/A
- CERS N/A
- EPS
- PSF N/A
- CERS N/A
- Revenue
- PSF N/A
- CERS $185,144,000.00
- Revenue This Year
- PSF N/A
- CERS $24.95
- Revenue Next Year
- PSF N/A
- CERS $11.88
- P/E Ratio
- PSF N/A
- CERS N/A
- Revenue Growth
- PSF N/A
- CERS 13.06
- 52 Week Low
- PSF $16.00
- CERS $1.12
- 52 Week High
- PSF $20.19
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- PSF 67.03
- CERS 39.38
- Support Level
- PSF $20.42
- CERS $1.34
- Resistance Level
- PSF $20.61
- CERS $1.41
- Average True Range (ATR)
- PSF 0.11
- CERS 0.07
- MACD
- PSF 0.02
- CERS -0.02
- Stochastic Oscillator
- PSF 86.44
- CERS 6.67
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.